References
- Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep. 2021;23(4). https://doi.org/10.1007/s11912-021-01029-7
- Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H. Systemic Distribution of Somatostatin Receptor Subtypes in Human: An Immunohistochemical Study. Endocr J. 2005;52(5):605-611. https://doi.org/10.1507/endocrj.52.605
- Deepa S, Vijay Sai K, Gowrishankar R, Rao D, Venkataramaniah K. Precision electron–gamma spectroscopic measurements in the decay of 177Lu. Applied Radiation and Isotopes. 2011;69(6):869-874. https://doi.org/10.1016/j.apradiso.2011.02.012
- Capala J, Graves SA, Scott A, et al. Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources. J Nucl Med. 2021;62(Supplement 3):3S-11S. https://doi.org/10.2967/jnumed.121.262749
- Staanum PF, Frellsen AF, Olesen ML, Iversen P, Arveschoug AK. Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Phys. 2021;8(1). https://doi.org/10.1186/s40658-021-00422-2
- Grassi E, Fioroni F, Berenato S, et al. Effect of image registration on 3D absorbed dose calculations in 177 Lu-DOTATOC peptide receptor radionuclide therapy. Physica Medica. 2018;45:177-185. https://doi.org/10.1016/j.ejmp.2017.11.021
- Goetz ThI, Lang EW, Prante O, et al. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent 177Lu-DOTATOC therapy. Ann Nucl Med. 2020;34(4):244-253. https://doi.org/10.1007/s12149-020-01440-3